New hope for brain cancer: drug targets Hard-to-Treat tumors
NCT ID NCT07485049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests an experimental drug, BGB-58067, in people with a newly diagnosed and aggressive brain cancer called glioblastoma. The drug is designed to work specifically in tumors missing a certain gene (MTAP). The study first checks if the drug reaches the brain and affects cancer cells, then expands to see if it helps patients live longer. About 78 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Joseph's Hospital and Medical Center
RECRUITINGPhoenix, Arizona, 85013, United States
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact